DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)

Authors
Category Primary study
JournalNeuro-Oncology
Year 2022
This article has no abstract
Epistemonikos ID: a81077d293f4cd7603ae0eadbfbb15b0f0fc3cdc
First added on: Feb 15, 2025